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Abstract 
Objective: Porphyromonas gingivalis (P. gingivalis) is a pathogen involved in periodontal disease. 
Recently, periodontal disease has been demonstrated to increase the risk of developing diabetes 
mellitus, although the molecular mechanism is not fully understood. Forkhead box protein O1 
(FoxO1) is a transcriptional factor that regulates gluconeogenesis in the liver. Gluconeogenesis is a 
key process in the induction of diabetes mellitus; however, little is known regarding the relationship 
between periodontal disease and gluconeogenesis. In this study, to investigate whether periodontal 
disease influences hepatic gluconeogenesis, we examined the effects of P. gingivalis on the 
phosphorylation and translocation of FoxO1 in insulin-induced human hepatocytes. 
 
Design: The human hepatocyte HepG2 was treated with insulin and Akt and FoxO1 phosphorylation 
was detected by western blot analysis. The localization of phosphorylated FoxO1 was detected by 
immunocytochemistry and western blot analysis. HepG2 cells were treated with SNAP26b-tagged P. 
gingivalis (SNAP-P. g.) before insulin stimulation, and then the changes in Akt and FoxO1 were 
determined by western blot analysis and immunocytochemistry.  
 
Results: Insulin (100 nM) induced FoxO1 phosphorylation 60 min after treatment in HepG2 cells. 
Phosphorylated FoxO1 translocated to the cytoplasm. SNAP-P.g. internalized into HepG2 cells and 
decreased Akt and FoxO1 phosphorylation induced by insulin. The effect of insulin on FoxO1 
translocation was also attenuated by SNAP-P.g.  
 
Conclusions: Our study shows that P. gingivalis decreases the phosphorylation and translocation of 
FoxO induced by insulin in HepG2 cells. Our results suggest that periodontal disease may increase 
hepatic gluconeogenesis by reducing the effects of insulin on FoxO1. 
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Highlights: 
1. We examined the effects of P. gingivalis on FoxO1-regulated hepatic gluconeogenesis. 
2. Insulin increased FoxO1 phosphorylation in HepG2 cells. 
3. The phosphorylated FoxO1 induced by insulin translocated to the cytoplasm. 
4. P. gingivalis attenuated the effects of insulin on FoxO1.  
5. P. gingivalis may increase gluconeogenesis by reducing insulin’s effects on FoxO1.  
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Introduction 
Porphyromonas gingivalis (P. gingivalis) is one of the primary pathogens involved in periodontal 
disease, which is chronic inflammation of the periodontal tissues that surround the tooth. Periodontal 
disease widely affects the adult population and the progress of periodontal disease results in tooth loss 
by the destruction of periodontal tissues. Thus, the prevention and treatment of periodontal disease 
have impacts on the patient’s quality of life (Needleman, McGrath, Floyd, & Biddle, 2004).  
It was recently shown that periodontal disease may not only cause tooth loss but also contribute to 
the development of systemic inflammation and diseases (Hajishengallis, 2015). Among these, the 
bidirectional relationship between diabetes mellitus and periodontal disease is well known (Taylor, 
Preshaw, & Lalla, 2013). For example, poor periodontal tissue status and tooth loss increased the 
level of glycated hemoglobin A1c (HbA1c) in patients without diabetes mellitus (Demmer et al, 
2010). Treatment with local minocycline in the periodontal pocket reduced HbA1c values in patients 
with type 2 diabetes (Iwamoto et al, 2001). After non-surgical periodontal therapy, P. gingivalis in 
subgingival plaque was detected more frequently in patients with increased HbA1c values compared 
to those with decreased values (Makiura et al, 2008). The results of these clinical studies suggest 
that periodontal disease has negative effects on glycemic control (Simpson, Needleman, Wild, 
Moles, & Mills, 2010). In contrast, many other studies showed that non-surgical periodontal therapy 
did not improve glycemic control in patients with type 2 diabetes (Christgau, Palitzsch, Schmalz, 
Kreiner, & Frenxel, 1998; Engebreston et al, 2013), and non-quantitative analysis was considered 
to cause the discrepant results (Janket, Wightman, Baird, Dyke, & Jones, 2005). The molecular 
mechanisms by which periodontal disease influences glucose metabolism in diabetes mellitus are not 
fully understood; thus, the question of whether periodontal disease is a risk factor for diabetes mellitus 
has not been resolved.  
To answer this question, we previously investigated whether oral P. gingivalis affects hepatic 
glycogen synthesis by using P. gingivalis tagged with the SNAP26b protein (SNAP-P. g.) to allow its 
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detection in mouse organs and cultured cells. We showed that SNAP-P. g., which is present in the oral 
cavity, was also detected in the liver, and the accumulation of hepatic glycogen tended to be 
attenuated in mice. SNAP-P. g. internalized in human hepatic HepG2 cells and decreased 
insulin-induced glycogen synthesis by inhibiting the Akt pathway (Ishikawa et al, 2013). Our results 
suggested that periodontal disease may increase the blood glucose levels in diabetes mellitus by 
inhibiting insulin-induced glycogen synthesis in the liver. 
 
In addition to glycogen synthesis, gluconeogenesis also participates in the maintenance of glucose 
homeostasis. Gluconeogenesis is a process that induces glucose synthesis in the liver from amino 
acids and glycerol under fasting conditions (Moore, Connolly, & Cherrington, 1998). In addition, 
the rate of hepatic gluconeogenesis is considered to increase in patients with type 2 diabetes mellitus. 
Gluconeogenesis is regulated by transcription factors such as forkhead box protein O1 (FoxO1). For 
example, after insulin binds to the insulin receptor (IR), insulin receptor substrate 1 (IRS1) is 
activated by phosphorylation (White, 2003). Activated IRS1 phosphorylates Akt and increases its 
kinase activity (Guo et al, 2009). Akt activation leads to the phosphorylation of FoxO1 in the 
nucleus. Phosphorylated FoxO1 then translocates to the cytoplasm and decreases its transcriptional 
activity, leading to the inhibition of gluconeogenesis by reducing the expression of gluconeogenic 
genes, such as phosphoenolpyruvate carboxykinase (PEPCK) and glucose 6-phosphatase (G6Pase) 
(Matsumoto, Pocai, Rossetti, Depinho, & Accili, 2007; Ayala et al, 1999). Finally, the 
inhibition of FoxO1 by insulin results in the attenuation of hepatic gluconeogenesis, and blood 
glucose levels are kept low in healthy subjects (Dong et al, 2008; Lu et al, 2012).  
These data indicate that gluconeogenesis is a critical mechanism to elevate the hepatic glucose 
output and to induce high levels of blood glucose in diabetes mellitus. However, little is known about 
the relationship between periodontal disease and hepatic gluconeogenesis. In the present study, we 
examined the effects of P. gingivalis on the phosphorylation and translocation of FoxO1 in HepG2 
cells. 
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Materials and Methods 
Materials 
Dulbecco's modified Eagle’s medium (DMEM), human recombinant insulin, and hemin were 
purchased from Wako Chemicals (Osaka, Japan). Brain heart infusion and yeast extract were obtained 
from BD Bioscience (Franklin Lakes, NJ, USA). 2-methyl-1,4-naphthoquinone (vitamin K3) was 
purchased from Tokyo Kasei (Tokyo, Japan). Antibodies against phospho-Akt (Ser473), FoxO1 
(C29H4), and phospho-FoxO1 (Thr 24)/FoxO3a (Thr 32) were obtained from Cell Signaling 
Technology (Danvers, MA, USA). Antibodies against β-actin and histone H3 were obtained from 
Sigma Aldrich (St Louis, MO, USA), and antibodies against B23 (C-19) and Eps15 (C-20) were 
obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA). 
 
Cell culture 
Human hepatocyte carcinoma HepG2 cells were plated in plastic dishes at a density of 10 × 104 cells/ 
mL and cultured in DMEM supplemented with 10% fetal bovine serum (FBS) at 37°C under a 
humidified atmosphere of 5% CO2. Cells were cultured for 3 days and used for experiments after 
reaching confluence.  
 
Bacterial culture and treatment with SNAP-P. g.  
We used the SNAP26b-tagged P. gingivalis (SNAP-P. g.), which was previously constructed.11 
Briefly, a shuttle vector containing the SNAP26b gene cloned under the control of the P. gingivalis 
endogenous trxB prompter was transformed into P. gingivalis ATCC33277. SNAP-P.g. was cultured 
in brain heart infusion containing 0.5% yeast extract, 10 µg/mL hemin, and 1 µg/mL 2-methyl-1, 
4-naphthoquinone (vitamin K3) in an anaerobic jar at 37°C.  
The cultured bacteria were centrifuged and washed twice with phosphate buffered saline (PBS). 
SNAP-P.g. was then suspended in PBS at 100 multiplicity of infection (MOI) and added to the 
cultured medium of HepG2 cells. The growth medium was replaced with 2% FBS DMEM and the 
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cells were incubated overnight before treatment with SNAP-P. g. Insulin (100 nM) was added for the 
indicated periods.  
 
Cellular fractionation  
HepG2 cells were collected and fractionation was performed using a CelLyticTM NuCLEARTM 
Extraction Kit (Sigma Aldrich) according to the manufacturer’s protocol with some modifications. 
Briefly, cells were scraped into lysis buffer (100 mM HEPES, pH 7.9, 15 mM MgCl2, and 100 mM 
KCL) and incubated on ice for 30 min. Then, 10% Igepal CA-630 solution was added to the swollen 
cells in lysis buffer to a final concentration of 0.6%. Cells were mixed, centrifuged at 10,000 g for 30 
s, and the supernatants were collected as the cytoplasmic fraction. The crude nucleic pellets were 
suspended in extraction buffer (20 mM HEPES, pH 7.9, 1.5 mM MgCl2, 0.42 M NaCl, 0.2 mM 
EDTA, and 25% (v/ v) glycerol) containing dithiothreitol (DTT) and protease inhibitor cocktail, 
mixed for 30 min, and centrifuged for 5 min at 10,000 g. The supernatants were collected as the 
nucleic fraction. 
 
SDS-PAGE and western blot analysis 
Cells were washed twice with PBS and then scraped into radioimmunoprecipitation assay (RIPA) 
buffer (1 mM DTT, 0.2 mM PMSF, 1 μg/mL leupeptin, 4 μg/mL aprotinin, and 50 mM NaF). Twelve 
micrograms of each sample were separated by SDS-PAGE and transferred to polyvinylidene fluoride 
membranes (Millipore, Medford, MA, USA). The membranes were incubated for 1 h at ambient 
temperature in 5% non-fat skim milk in PBS containing 0.05% Tween-20 (PBS-Tween), and then 
incubated overnight at 4°C in blocking solution containing specific antibodies (diluted at 1:1000). 
After washes in PBS-Tween, the membranes were incubated for 1 h at room temperature in blocking 
solution containing horseradish peroxidase-conjugated secondary antibodies (diluted at 1:5000). The 
membranes were then washed and the proteins recognized by the antibodies were visualized with an 
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Immobilon Western Chemiluminescent HRP Substrate (Merck Millipore Corp, MA, USA) according 
to the manufacturer's instructions.  
 
Immunocytochemistry 
HepG2 cells were cultured on sterile 18-mm round coverslips, and immunocytochemistry was 
performed as described previously (Yoshida et al, 2012). Briefly, the cells were fixed with 3% 
formalin for 30 min and then permeabilized with 0.1% Triton X-100 in PBS for 2 min on ice. After 
blocking with 4% BSA in PBS for 1 h, the cells were incubated with anti-phospho-FoxO1 antibody or 
normal rabbit IgG overnight at 4°C, followed by Alexa Fluor 488-conjugated anti-rabbit IgG. The 
cells were then treated with Hoechst 33342 for nuclear staining. The samples were mounted and 
observed using an inverted fluorescence microscope (ECLIPSE Ti-U, Nikon, Tokyo). Images were 
acquired using an ECLIPSE Ti-U microscope with NIS-Elements software (Nikon, Tokyo, Japan). 
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Results 
Insulin increased the phosphorylation and translocation of FoxO1 in HepG2 cells 
To examine the effect of insulin on FoxO1 in HepG2 cells, we first treated the cells with 100 nM 
insulin for 0 to 60 min and determined the expression of phosphorylated-FoxO1 and FoxO1 proteins 
by western blot. The phosphorylation of FoxO1 on threonine 24 was induced after 60 min of exposure 
to insulin (Fig. 1A).  
FoxO1 is known to translocate to the cytoplasm from the nucleus after its phosphorylation, and its 
activity as a transcription factor decreases. We therefore determined whether FoxO1 localization 
changed after insulin treatment in HepG2 cells. The immunocytochemistry results showed that 
phosphorylated FoxO1 was detected in the nucleus of untreated cells (Fig. 1B, a). In contrast, 30 min 
and 60 min after treatment with 100 nM insulin, phosphorylated FoxO1 translocated to the cytoplasm 
(Fig. 1B, b and c). Hoechst 33342 staining of nuclei (Fig. 1B, d, e, and f) and the merged images (Fig. 
1B, g, h, and i) are shown.  
To confirm the results presented in Figure 1B, cytosolic and nuclear proteins were prepared from 
the cells treated with or without insulin and analyzed by western blot. As shown in Figure 1C, the 
presence of the phosphorylated FoxO1 protein in the cytosolic fraction increased 60 min after 
treatment with 100 nM insulin compared to that in the untreated cells (Fig. 1C, upper panel). The 
purity of the nuclear (Fig. 1C, middle panel) and cytosolic fractions (Fig. 1C, bottom panel) was 
confirmed using antibodies against B23 and Eps15, respectively.  
 
SNAP-P. g. internalized into HepG2 cells and attenuated the insulin-induced Akt/FoxO1 
pathway 
Because P. gingivalis is known to internalize in host cells and express its virulence, we first 
confirmed whether P. gingivalis also invaded human HepG2 cells. To detect P. gingivalis within the 
cells, we used the previously constructed SNAP26b-tagged P. gingivalis (SNAP-P.g.) (8). The cells 
were incubated with SNAP-P.g. at a concentration of 100 MOI for 0 to 6 h, and SNAP-P.g. was 
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detected by western blot using an anti-SNAP26b antibody. As shown in Figure 2A, the intensity of 
the band corresponding to SNAP26b increased in a time-dependent manner up to 6 h, indicating that 
SNAP-P.g. internalized into HepG2 cells.  
Next, we examined the effects of SNAP-P.g. on the insulin-induced Akt/FoxO1 pathway in HepG2 
cells. HepG2 cells were treated with insulin for 30 min after incubation with or without 100 MOI of 
SNAP-P.g. for 6 h. Akt phosphorylation on serine 473 was then determined by western blot. The level 
of phosphorylated Akt increased after insulin treatment (Fig. 2B, lane 2). Pre-incubation with 
SNAP-P.g. decreased the rate of Akt phosphorylation induced by insulin (Fig. 2B, lane 3). Moreover, 
in HepG2 cells treated with 100 nM insulin for 60 min, FoxO1 phosphorylation on threonine 24 
increased compared with that of untreated cells (Fig. 2C, lane 1 and 2). This effect of insulin on 
FoxO1 phosphorylation was suppressed by pre-incubation with SNAP-P.g. for 6 h (Fig. 2C, lane 3). 
SNAP-P.g. itself did not affect FoxO1 phosphorylation (Fig. 2C, lane 4).  
 
SNAP-P. g. inhibited the insulin-induced translocation of FoxO1 in HepG2 cells 
We further verified whether SNAP-P.g. affected the translocation of FoxO1 regulated by insulin. 
HepG2 cells were incubated with or without 100 nM of insulin for 60 min after treatment with 100 
MOI of SNAP-P.g. for 6 h. FoxO1 localization was then detected by immunocytochemistry and 
western blot.  
In insulin-treated cells, the accumulation of phosphorylated FoxO1 in the cytoplasm was increased 
when compared with that of untreated cells (Fig. 3A, a and b). SNAP-P.g. inhibited the 
insulin-induced translocation of phosphorylated FoxO1 to the cytoplasm (Fig. 3A, c). The localization 
of phosphorylated-FoxO1 was not altered in cells treated with SNAP-P.g. only (Fig. 3A, d). The 
nuclei were stained with Hoechst 33342 (Fig. 3A, e to h) and images were merged (Fig. 3A, i to l). 
Images of cells stained with normal rabbit IgG instead of anti-phospho-FoxO1 antibody (negative 
control) are shown in Figure 3B. 
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We next prepared cytosolic and nuclear proteins from the cells and detected the localization of 
phosphorylated FoxO1 by western blot. Consistent with the results presented in Figure 3A, insulin 
treatment induced the translocation of phosphorylated FoxO1 to the cytoplasmic fraction (Fig. 3C, 
lane 1 and 4), and this effect of insulin on phosphorylated FoxO1 translocation was inhibited by 
SNAP-P.g. (Fig. 3C, lane 3). 
 
12 
 
Discussion 
P. gingivalis is an oral bacterium that is generally found within gingival tissues and dental plaque. P. 
gingivalis is also known to invade the cardiac endothelium (Deshpande, Khan, & Genco, 1998) 
and spread into the bloodstream in patients with periodontitis (Castillo et al, 2011). Additionally, P. 
gingivalis is considered to evade circulating phagocytes by adhering to erythrocytes (Belstrom et al, 
2011). Indeed, we previously found that SNAP-P. g. was detected in the liver of mice orally infected 
with SNAP-P.g. Additionally, it was detected at a high frequency in mice with high blood glucose 
levels (Ishikawa et al, 2013). These observations suggest that oral P. gingivalis probably translocates 
to the liver through systemic circulation and is implicated in hepatic gluconeogenesis. We therefore 
used hepatic HepG2 cells to investigate the effects of P. gingivalis on gluconeogenesis in the present 
study. To investigate association between oral bacteria and glucose metabolisms in the liver is 
important for understanding the mechanisms by which periodontal disease influences diabetes 
mellitus. However, there are few reports showing the relationship between oral bacteria and hepatic 
gluconeogenesis. This is the first report indicating that P. gingivalis is associated with  
gluconeogenesis by regulating FoxO1 in insulin-treated HepG2 cells. 
FoxO1 increases hepatic glucose production in response to insulin (Matsumoto, Pocai, Rossetti, 
Depinho, & Accili, 2007). There are four FoxO proteins in mammals: FoxO1, FoxO3, FoxO4, and 
FoxO6. Among these, FoxO1 is known to participate in glucose production in the liver (Haeusler, 
Kaestner, & Accili, 2010; Zhang et al, 2012). Thus, in the present study, we focused on FoxO1 in 
HepG2 cells treated with insulin and/or SNAP-P.g.  
Akt is phosphorylated in response to insulin and plays critical roles in regulating both glycogen 
synthesis and gluconeogenesis in the liver. Because FoxO1 contains potential Akt phosphorylation 
sites (Nakae, Park, & Accili, 1999), we verified the phosphorylation status of both Akt and FoxO1 
in insulin-treated HepG2 cells. Our results showed that Akt was phosphorylated 30 min after 
treatment with insulin (Fig. 2B). In contrast, the phosphorylation and translocation of FoxO1 was 
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induced 60 min after treatment with insulin following Akt phosphorylation (Fig. 1A). When HepG2 
cells were infected with SNAP-P.g. for 6 h, the effect of insulin on Akt phosphorylation was inhibited 
(Fig. 2B). SNAP-P. g. internalization also decreased the effects of insulin on the phosphorylation and 
translocation of FoxO1 (Fig. 3A and C). These results suggest that SNAP-P. g. is internalized into 
HepG2 cells and decreases FoxO1 phosphorylation, probably by inhibiting insulin-induced Akt 
phosphorylation.  
Although the Akt-dependent inactivation of FoxO1 is considered to be essential for the 
insulin-induced suppression of hepatic glucose output after feeding, Lu et al. (2012) reported that the 
genetic manipulation of Akt and FoxO1 does not affect insulin signaling and metabolic responses, 
suggesting an alternative mechanism through which liver responds to insulin signaling under some 
conditions in vivo. In the present study, we examined the effect of P. gingivalis on insulin signaling 
using HepG2 cells in vitro but not in vivo. It also remains unknown whether P. gingivalis affects the 
transcription activity of FoxO1 and the expression of its regulatory genes that are involved in 
gluconeogenesis, such as PEPCK and G6Pase. Further studies are needed to investigate whether our 
results shown in this study can be observed in mouse livers infected with P. gingivalis in vivo and 
whether the inhibitory effects of P. gingivalis on hepatic insulin signaling result in abnormal 
gluconeogenesis.  
Furthermore, the mechanism by which SNAP-P.g. decreases Akt phosphorylation was not 
elucidated in this study. P. gingivalis presents many virulence factors that promote periodontal disease 
such as fimbriae, lipopolysaccharide (LPS), and cysteine proteinases. Moreover, it is considered that 
the ability of P. gingivalis to adhere to and invade host cells is critical to express its virulence 
(Lamont, & Yilmaz, 2002; Tribble, Mao, James, & Lamont, 2006). Recently, it was reported 
that gingipains, P. gingivalis cysteine proteinases, inactivated Akt phosphorylation on threonine 308 
and serine 473 in human gingival epithelial cells (Nakayama, Inoue, Naito, Nakayama, & Ohara, 
2015). LPS from P. gingivalis also suppressed Akt kinase activity in rat sublingual acinar cells 
(Slomiany, B. L., & Slomiany, A, 2011). Moreover, in our preliminary experiments, 
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heat-inactivated SNAP-P.g., which was incubated for 10 min at 100°C, did not internalize into HepG2 
cells, and insulin-induced Akt phosphorylation was not altered (data not shown). Based on these 
observations, it is likely that some gingipains and the internalization of SNAP-P. g. play important 
roles in the inhibition of FoxO1 phosphorylation and translocation. To understand the role of P. 
gingivalis in hepatic gluconeogenesis, further studies investigating which P. gingivalis factors 
regulate the Akt/FoxO1 pathway and whether the internalization of P. gingivalis into host cells is 
critical for its effects are needed. 
 
In conclusion, we demonstrated that P. gingivalis internalizes into human hepatocytes, HepG2 cells, 
and attenuates the insulin-induced activation of the Akt/FoxO1 pathway. Our results suggest that 
periodontal disease may increase hepatic gluconeogenesis by reducing the effects of insulin on 
FoxO1. 
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 Figures  
Figure 1: Insulin induces the phosphorylation and translocation of FoxO1 in HepG2 cells  
HepG2 cells were treated with 100 nM of insulin for 0 to 60 min. (A) Cells were subjected to western 
blot analysis with anti-phospho-FoxO1 (pFoxO1), FoxO, and β-actin. A representative data of three 
separate experiments is shown. (B). Localization of phosphorylated FoxO1 detected by 
immunocytochemistry using an anti-phospho-FoxO1 antibody (green, a, b, and c). Hoechst 33342 was 
used to stain the nuclei (blue, d, e, and f). Microscopic images of the same field were taken and 
merged (g, h, and i). (C). Nuclear (Nucleus) and cytosolic (Cytoplasm) fractions were prepared from 
the cells. Each sample was subjected to western blot analysis with anti-phospho-FoxO1 (pFoxO1), 
B23, and Eps15 antibodies. The immunoblots shown are representative of three separate experiments. 
 
Figure 2: SNAP-P.g. internalizes into HepG2 cells and decreases insulin-induced Akt/FoxO1 
phosphorylation  
(A) HepG2 cells were treated with 100 MOI of SNAP-P.g. for up to 6 h. The presence of SNAP26b 
within the cells was analyzed by western blot using an anti-SNAP26b and β-actin antibody. The 
arrow indicates SNAP26b-specific bands; ns, non-specific bands. A representative data of three 
separate experiments is shown. (B), (C) HepG2 cells were pretreated with 100 MOI of SNAP-P.g for 
6 h and then treated with or without 100 nM insulin for 30 min (B) or 60 min (C). Cell lysates were 
analyzed by western blot using an anti-phospho-Akt (pAkt), Akt, phospho-FoxO1 (pFoxO1), FoxO1, 
and β-actin antibody. The immunoblots shown are representative of three separate experiments. 
 
Figure 3: SNAP-P.g. inhibits insulin-induced FoxO1 translocation in HepG2 cells  
HepG2 cells were pretreated with 100 MOI of SNAP-P.g. for 6 h and then treated with or without 100 
nM insulin for 60 min. (A) Phosphorylated FoxO1 (pFoxO1, green, a to d) was detected by 
immunocytochemistry using an anti-phospho-FoxO1 antibody and a fluorescence microscope. 
Hoechst 33342 was used to stain the nuclei (blue, e to h). Microscopic images of the same field were 
 taken and merged (i to l). (B) As a negative control, cells stained with normal rabbit IgG instead of 
anti-phospho-FoxO1 are shown. (C) Nuclear (Nucleus) and cytosolic (Cytoplasm) fractions were 
prepared from the cells. Each sample was subjected to western blot analysis with an 
anti-phospho-FoxO1 (pFoxO1), histone H3, and Eps15 antibody. A representative data of three 
separate experiments is shown. 
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